TCG Advisory Services LLC Invests $91,000 in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

TCG Advisory Services LLC acquired a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 15,000 shares of the company’s stock, valued at approximately $91,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Principal Financial Group Inc. raised its stake in Amneal Pharmaceuticals by 10.3% during the 3rd quarter. Principal Financial Group Inc. now owns 54,432 shares of the company’s stock valued at $230,000 after acquiring an additional 5,092 shares in the last quarter. Gladius Capital Management LP acquired a new position in shares of Amneal Pharmaceuticals during the 3rd quarter valued at $39,000. Sherbrooke Park Advisers LLC bought a new stake in Amneal Pharmaceuticals in the third quarter worth about $54,000. Raymond James & Associates raised its holdings in shares of Amneal Pharmaceuticals by 12.4% in the 3rd quarter. Raymond James & Associates now owns 181,387 shares of the company’s stock worth $765,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Aigen Investment Management LP bought a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter worth $118,000. 31.82% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

AMRX has been the topic of several research analyst reports. The Goldman Sachs Group lifted their price objective on shares of Amneal Pharmaceuticals from $6.25 to $8.00 and gave the stock a “buy” rating in a research report on Monday. Piper Sandler raised their price target on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. StockNews.com lowered Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, March 4th. Barclays raised their price target on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Monday, January 29th. Finally, Truist Financial reaffirmed a “buy” rating and set a $9.00 target price (up previously from $7.00) on shares of Amneal Pharmaceuticals in a research report on Monday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $8.25.

Amneal Pharmaceuticals Trading Down 1.6 %

Shares of AMRX opened at $6.65 on Tuesday. The firm’s 50 day moving average price is $5.78 and its two-hundred day moving average price is $5.32. The company has a quick ratio of 0.97, a current ratio of 1.65 and a debt-to-equity ratio of 121.31. Amneal Pharmaceuticals, Inc. has a twelve month low of $1.74 and a twelve month high of $6.90.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its earnings results on Friday, March 1st. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.07. The firm had revenue of $616.98 million during the quarter, compared to analysts’ expectations of $630.67 million. Amneal Pharmaceuticals had a positive return on equity of 234.06% and a negative net margin of 6.76%. As a group, research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.5 earnings per share for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.